Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
20
Today In Oncology
Mocertatug Rezetecan (Mo-Rez) Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
National Academy of Medicine Elects 100 New Members for 2026
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
ASH Issues New Recommendations for the Management of Myelofibrosis
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo